Modulation of infiltrating CD206 + macrophages restricts progression of pulmonary lymphangioleiomyomatosis
European Respiratory Journal · 2025
DOI: 10.1183/13993003.00084-2025 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Respiratory Journal, 2025. Verfasst von Heng-Jia Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Infection, Immunity and Cancer, Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Haining, Ch…. Hauptthemen laut MEDLINE: Lymphangioleiomyomatosis, Macrophages, Lung Neoplasms, Mannose-Binding Lectins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Fondation du Souffle, Fondation de l'Avenir pour la Recherche Médicale Appliquée.
Abstract (Originalsprache)
Rationale
Lymphangioleiomyomatosis (LAM) is a low-grade neoplasm caused by the proliferation of tuberous sclerosis complex (TSC) 1- or TSC2-deficient LAM cells, resulting in progressive cystic lung disease. The currently approved treatment for LAM delays disease progression but the disease recurs if treatment is discontinued. Therefore, new therapeutic targets and/or strategies are necessary for a cure. Immunosuppressive M2-like macrophages are involved in the progression of various cancers, but their role in the pathophysiology of LAM and as a putative therapeutic target is unknown.
Methods
To identify the different immune cell populations involved in LAM, we generated a single-cell transcriptomic map of pulmonary LAM. Interactions between macrophages and LAM cells were studied using the Visium spatial transcriptomic platform and immunofluorescence staining on human pulmonary LAM specimens. Direct co-culture models were used to characterise the influence of TSC2-deficient cells on macrophage differentiation. The efficacy of targeting M2-like macrophages was assessed in preclinical mouse models of TSC2-deficient subcutaneous tumours treated with RP-182, a synthetic peptide which reprogrammes macrophages towards an antitumour M1-like phenotype.
Results
Single-cell RNA-sequencing analysis revealed that the majority of macrophages in pulmonary LAM display immunosuppressive markers, including CD206/MRC1 and CD163 . Spatial transcriptomic and immunofluorescence analyses showed that M2 macrophages are in close proximity to LAM cells and that LAM cells that are in close proximity to macrophages highly express macrophage-homing factor chemokine ligand CXCL12 . In vitro , co-culture of human and mouse macrophages with TSC2-deficient cells resulted in the upregulation of M2-marker-expressing macrophages. Targeting M2 macrophages via treatment with the CD206 modulator RP-182 impaired the growth of TSC2-deficient tumours in vivo .
Conclusion
LAM cells recruit and polarise macrophages towards an M2 phenotype. M2-like CD206 high macrophages may represent a potential therapeutic target in LAM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Infection, Immunity and Cancer, Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Haining, China hengjialiu@intl.zju.edu.cn.
- Edinburgh Medical School: Biomedical Sciences, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
- Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
- H-J. Liu and R. Diesler contributed equally to this work.
- Department of Respiratory Medicine, National Reference Centre for Rare Pulmonary Diseases, ERN-LUNG, Louis Pradel Hospital, Hospices Civils de Lyon and UMR754, INRAE, Claude Bernard University Lyon 1, Lyon, France.
- Center for Infection, Immunity and Cancer, Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Haining, China.
ORCID-Profile: Vincent Cottin
Förderung
- NIDDK NIH HHS
- Fondation du Souffle
- Fondation de l'Avenir pour la Recherche Médicale Appliquée
- Lucy Engles Fund for TSC and LAM Research
- Mary Jean Stempien, MD and James W Stricker, MD
- CSL Behring
Zitieren
APA
Liu, H. J., Diesler, R., Chami, J., Wu, B., Du, H., Jin, Y., Daou, M., Alesi, N., Khabibullin, D., Leroux, C., Cottin, V., Cantley, L. G., Rudloff, U., & Henske, E. P. (2025). Modulation of infiltrating CD206 + macrophages restricts progression of pulmonary lymphangioleiomyomatosis. European Respiratory Journal. https://doi.org/10.1183/13993003.00084-2025
Vancouver
Liu HJ, Diesler R, Chami J, Wu B, Du H, Jin Y, et al. Modulation of infiltrating CD206 + macrophages restricts progression of pulmonary lymphangioleiomyomatosis. European Respiratory Journal. 2025. doi:10.1183/13993003.00084-2025
BibTeX
@article{Liu2025,
author = {Liu, Heng-Jia and Diesler, Remi and Chami, Joelle and Wu, Boxiang and Du, Heng and Jin, Yue and Daou, Melissa and Alesi, Nicola and Khabibullin, Damir and Leroux, Caroline and Cottin, Vincent and Cantley, Lloyd G and Rudloff, Udo and Henske, Elizabeth P},
title = {Modulation of infiltrating CD206 + macrophages restricts progression of pulmonary lymphangioleiomyomatosis},
journal = {European Respiratory Journal},
year = {2025},
doi = {10.1183/13993003.00084-2025}
}
EUVIMED